Literature DB >> 17009069

Neurosarcoidosis--a diagnostic pitfall with consequences.

Irene Kapfhammer1, Christine Armbruster, Christian Armbruster.   

Abstract

Neurosarcoidosis is often a diagnostic dilemma, especially in the absence of other organ involvement. We report a 64-year-old patient who had suffered from paraplegia due to an intramedullar process since 1995. The presumptive diagnosis based on computed tomography was spinal cord infarction. Six years later, he complained about increasing paresthesia. Magnetic resonance imaging of the spinal cord showed nodular meningeal enhancement. Computed tomography of the thorax revealed mediastinal and hilar lymphadenopathy. Bronchoscopy under generalized anesthesia was performed. The differential cell count in bronchoalveolar lavage fluid showed 39% lymphocytes and a CD4(+)/CD8(+) ratio of 17.7. Histological examination of biopsy specimens from the hilar lymph nodes revealed non-necrotizing granulomas with epitheloid cells and Langerhans-type giant cells, consistent with the diagnosis of sarcoidosis. As a result of these findings, lumbar puncture was undertaken and a raised protein concentration and pleocytosis were found in the cerebrospinal fluid. The number of lymphocytes (9,250 lymphocytes/l) and a CD4(+)/CD8(+) ratio of 10.78 led to the diagnosis of neurosarcoidosis. Paralysis might have been prevented if the correct diagnosis of neurosarcoidosis had been established earlier in this patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009069     DOI: 10.1007/s00508-006-0662-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  16 in total

1.  Spinal cord sarcoidosis: a diagnostic dilemma.

Authors:  F C Viñas; S Rengachary; W J Kupsky
Journal:  Neurol Res       Date:  2001-06       Impact factor: 2.448

2.  CSF-ACE activity in probable CNS neurosarcoidosis.

Authors:  Albert J Tahmoush; Mary S Amir; William W Connor; James K Farry; Sevastian Didato; Alice Ulhoa-Cintra; Jennifer M Vasas; Robert J Schwartzman; Harold L Israel; Herbert Patrick
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2002-10       Impact factor: 0.670

Review 3.  Neurosarcoidosis: a review of its intracranial manifestation.

Authors:  D A Nowak; D C Widenka
Journal:  J Neurol       Date:  2001-05       Impact factor: 4.849

Review 4.  Neurologic manifestations of sarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

Review 5.  CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis?

Authors:  U Costabel
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

Review 6.  Update of ocular manifestations in sarcoidosis.

Authors:  Yoshihiko Usui; Elizabeth D E Kaiser; Robert F See; Narsing A Rao; Om P Sharma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2002-10       Impact factor: 0.670

7.  The role of MRI and nerve root biopsy in the diagnosis of neurosarcoidosis.

Authors:  F G Moore; F Andermann; J Richardson; D Tampieri; R Giaccone
Journal:  Can J Neurol Sci       Date:  2001-11       Impact factor: 2.104

8.  The Cheshire Cat Syndrome: an unusual case of neurosarcoidosis.

Authors:  Om P Sharma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2003-06       Impact factor: 0.670

9.  A prospective study of 32 patients with neurosarcoidosis.

Authors:  Roger K A Allen; Ross E Sellars; Paul A Sandstrom
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2003-06       Impact factor: 0.670

10.  Neurosarcoidosis: clinical experience and diagnostic pitfalls.

Authors:  C Kellinghaus; M Schilling; P Lüdemann
Journal:  Eur Neurol       Date:  2004-01-28       Impact factor: 1.710

View more
  1 in total

1.  Neurosarcoidosis: unusual presentations and considerations for diagnosis and management.

Authors:  Walid Radwan; Brandon Lucke-Wold; Ibrahim Ahmed Robadi; Kymberly Gyure; Thomas Roberts; Sanjay Bhatia
Journal:  Postgrad Med J       Date:  2016-12-05       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.